# US 2011/0086821 A1 · Tetracycline Compounds for Treatment of Cryptosporidium Parvum Related Disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0086821 A1
- Document ID: US20110086821A1
- Status: Published application
- Kind: A1
- Application number: 12/897,459
- Filed: 2010-10-04
- Published: 2011-04-14
- Earliest claimed: 2000-01-24
- Assignees: Trustees of Tufts College
- Inventors: Stuart B. Levy; Mark L. Nelson
- Web page: https://patentgrep.com/patent/US20110086821A1

## CPC

- A61K 31/65: Tetracyclines
- A61P 1/12: Antidiarrhoeals
- A61P 33/00: Antiparasitic agents
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- C07C 237/26: of a ring being part of a condensed ring system formed by at least four rings, e.g. tetracycline
- C07C 2601/10: the ring being unsaturated
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Methods and compositions for treating Cryptosporidium parvum related disorders in a mammal are discussed. Several novel tetracycline compounds useful for treating Cryptosporidium parvum related disorders are also included.

## Claims

### Claim 1

A method for controlling Cryptosporidium parvum in a mammal, comprising administering to said mammal an effective amount of a tetracycline compound, such that Cryptosporidium parvum is controlled in said mammal.

### Claim 2

A pharmaceutical composition comprising an effective amount of a tetracycline compound to treat a Cryptosporidium parvum related disorder in a mammal and a pharmaceutically acceptable carrier.

### Claim 3

A compound selected from the group consisting of:
and pharmaceutically acceptable salts thereof.

### Claim 4 (depends on 3)

The compound of claim 3, wherein said compound is:
or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 3)

The compound of claim 3, wherein said compound is:
or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 3)

The compound of claim 3, wherein said compound is:
or a pharmaceutically acceptable salt thereof.
